775 related articles for article (PubMed ID: 22564582)
21. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
[TBL] [Abstract][Full Text] [Related]
22. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
23. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
[TBL] [Abstract][Full Text] [Related]
24. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
25. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
Murakami R; Amada N; Sato T; Orii T; Kikuchi H; Haga I; Ohashi Y; Okazaki H
Clin Transplant; 2006; 20(3):351-8. PubMed ID: 16824154
[TBL] [Abstract][Full Text] [Related]
26. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
Yuefeng M; Weili F; Wenxiang T; Ligang X; Guiling L; Hongwei G; Wencai L; Xiaoguang W; Wei M; Zhongyi F
Clin Transplant; 2011; 25(4):517-22. PubMed ID: 20560989
[TBL] [Abstract][Full Text] [Related]
28. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
[TBL] [Abstract][Full Text] [Related]
29. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation.
Shitrit AB; Kramer MR; Bakal I; Morali G; Ben Ari Z; Shitrit D
Ann Thorac Surg; 2006 May; 81(5):1851-2. PubMed ID: 16631684
[TBL] [Abstract][Full Text] [Related]
30. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
[TBL] [Abstract][Full Text] [Related]
31. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
32. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.
Lee WC; Wu MJ; Cheng CH; Chen CH; Shu KH; Lian JD
Am J Kidney Dis; 2001 Nov; 38(5):1074-81. PubMed ID: 11684562
[TBL] [Abstract][Full Text] [Related]
33. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine.
Nery JR; Nery-Avila C; Reddy KR; Cirocco R; Weppler D; Levi DM; Nishida S; Madariaga J; Kato T; Ruiz P; Schiff E; Tzakis AG
Transplantation; 2003 Apr; 75(8):1179-86. PubMed ID: 12717200
[TBL] [Abstract][Full Text] [Related]
34. Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients.
Radhakrishnan K; Chi A; Quan DJ; Roberts JP; Terrault NA
Transplantation; 2017 Sep; 101(9):2079-2082. PubMed ID: 28880197
[TBL] [Abstract][Full Text] [Related]
35. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
Wiegand J; Wedemeyer H; Finger A; Heidrich B; Rosenau J; Michel G; Bock CT; Manns MP; Tillmann HL
Antivir Ther; 2008; 13(4):547-54. PubMed ID: 18672533
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.
Buti M; Tabernero D; Mas A; Homs M; Prieto M; Rodríguez-Frías F; Casafont F; Casillas R; González A; Miras M; Herrero JI; Castells L; Esteban R
Transpl Infect Dis; 2015 Apr; 17(2):208-20. PubMed ID: 25641570
[TBL] [Abstract][Full Text] [Related]
37. HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience.
Yuan CH; Xiu DR; Jiang B; Li ZF; Li L; Song SB; Zhang TL
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):149-53. PubMed ID: 23558068
[TBL] [Abstract][Full Text] [Related]
38. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.
Roque-Afonso AM; Feray C; Samuel D; Simoneau D; Roche B; Emile JF; Gigou M; Shouval D; Dussaix E
Gut; 2002 Jan; 50(1):95-9. PubMed ID: 11772974
[TBL] [Abstract][Full Text] [Related]
39. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
[TBL] [Abstract][Full Text] [Related]
40. Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience.
Liu CJ; Lai MY; Lee PH; Chou NK; Chu SH; Chen PJ; Kao JH; Jen YM; Chen DS
J Gastroenterol Hepatol; 2001 Sep; 16(9):1001-8. PubMed ID: 11595064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
